FCGR2A and cancer: In this study, we examined the anti-cancer effects of a therapeutic anti-human PD-1 antibody (nivolumab, OPDIVO; Bristol Myers SquibbTM, NY, USA), using a NOG-FcγR−/− mouse, in which FcγR expression is absent due to disruptions of the Fcer1g and Fcgr2b genes.